New Two-Drug attack on Tough-to-Treat breast cancer
NCT ID NCT07441512
Summary
This study is testing whether combining two drugs, inavolisib and eribulin, can help control advanced triple-negative breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after at least one prior treatment. It will enroll about 26 patients to see how well the combination works and how safe it is. The trial will proceed in two stages, with the second stage only starting if enough patients respond well in the first stage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.